NCT03667547View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of Raltegravir (MK-0518) in Healthy Japanese Male Participants (MK-0518-851)

PHASE4CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 27, 2018

Primary Completion Date

October 23, 2018

Study Completion Date

October 23, 2018

Conditions
Human Immunodeficiency Virus (HIV) Infection
Interventions
DRUG

Raltegravir

Raltegravir 600 mg tablet

Trial Locations (1)

171-0014

Medical Corporation Houeikai Sekino Clinical Pharmacology Clinic ( Site 0001), Tokyo

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT03667547 - Safety, Tolerability, and Pharmacokinetics of Raltegravir (MK-0518) in Healthy Japanese Male Participants (MK-0518-851) | Biotech Hunter | Biotech Hunter